Long-term remission with temozolomide for AIDS-related primary central nervous system lymphoma.

Primary Central Nervous System Lymphoma (PCNSL) is an aggressive brain tumour with a median survival rarely exceeding 3 months without treatment when seen in association with advanced HIV. High dose methotrexate (HD-MTX) in association with combination antiretroviral therapy (cART) is the recommended chemotherapy. However, HD-MTX may be not feasible due to poor performance status and concerns about toxicity. The 2023 guidelines from the European Association of Neuro-Oncology recommend that for people living with HIV (PLWH) presenting with PCNSL who have morbidities and/or poor functional status precluding the safe use of HD-MTX, other agents with a more favorable toxicity profile such as temozolomide might be considered. However, reports of temozolomide use for PLWH presenting PCNSL are exceedingly rare and this recommendation is extrapolated from its use in immunocompetent patients. We report here an elderly man living with HIV, with PCNSL and poor performance status who achieved long lasting remission with temozolomide plus cART. Our case illustrates the potential effectiveness of temozolomide in association with cART as first line treatment for PCNSL in a patient with poor functional status.